Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
What is your experience and treatment efficacy of tucatinib if used after enhertu in metastatic breast cancer?
Related Questions
Given possible lack of benefit findings in subset analysis of Monarch 3, would you still use Abemaciclib in a postmenopausal woman with high-risk ER+ breast cancer?
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
In which scenarios do you stage breast cancer using CT and nuclear bone scans versus PET-CT?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
What are your top takeaways in Breast Cancer from ASCO 2024?
Is there a role for Elacestrant in ER+ metastatic breast cancer with ESR1-YAP1 fusion on NGS?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
How, if at all, do you use changes in SUV on a PET-CT to assess for disease progression/response in patients with metastatic breast cancer?
What disease characteristics will guide your choice of alpelisib plus fulvestrant (per SOLAR-1) versus capivasertib plus fulvestrant (per CAPItello-291) in PIK3CA mutated advanced ER+/HER2- breast cancer after progression on 1L ET regimen, given both are now approved in this population?
